Work

Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs)